Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522786 | 0.95 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20511627 | 0.91 | CA12 (0.47) | ALPLCA12CA1CA2CA7 | |
| SCHEMBL24436889 | 0.85 | CA12 (0.48) | ALPLCA12CA1CA2CA7 | |
| SCHEMBL1418414 | 0.85 | PDGFRB (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL365903 | 0.85 | MAPT (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23906095 | 0.85 | CA12 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14186809 | 0.85 | MAPT (0.41) | ALPLCA12CA1CA2CA7 | |
| SCHEMBL534847 | 0.84 | GAA (0.46) | ALPLKDM4EGAALMNAPOLB | |
| SCHEMBL17700427 | 0.84 | KDM4E (0.50) | KDM4EGAALMNAPOLBALDH1A1 | |
| SCHEMBL21274815 | 0.84 | KDM4E (0.55) | KDM4EGAALMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-122070277-A | Androgen receptor PROTAC | 葛兰素史密斯克莱知识产权发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025061906-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| CN-119365456-A | Compounds as BCL-2 inhibitors | 重庆复创医药研究有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-114478520-B | Bcl-2 protein apoptosis inducer and application thereof | 杭州和正医药有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118955560-A | Light-induced polyfluoroaromatic hydrocarbon phosphonation process | 南京师范大学 | 2024-11-15 | — | — | CN | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| EP-1907383-A1 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-5175356-A | Trifluorobenzoic acid intermediates | WARNER-LAMBERT COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | ALPL 4606/4885CA12 4792/4885CA1 4864/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | ALPL 4468/4885CA12 1389/4885CA1 541/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | ALPL 2803/4885CA12 4466/4885CA1 4368/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | ALPL 4468/4885CA12 1389/4885CA1 541/4885 |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | ALPL 1437/4885CA12 4687/4885CA1 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.